Medable Newsroom
Medable Launches Innovation Evidence Workshop – First Collaboration To Bring Leaders Together on DCT Impact, Adoption, and Best Practices
Medable, the leading provider of AI-powered clinical trial technology, today announced its Innovation Evidence Workshop series, developed in collaboration with and facilitated by the Tufts Center for the Study of Drug Development (Tufts CSDD). Leaders from 20 pharmaceutical, biotech, and contract research organizations (CROs) participated in the inaugural invitation-only workshop held on November 19 in Boston, MA. Programming featured representatives from the U.S. Food and Drug Administration, global pharmaceutical companies, leading contract research organizations (CROs), Harvard MRCT, Tufts CSDD, and Medable.
Releases
Medable Launches Innovation Evidence Workshop – First Collaboration To Bring Leaders Together on DCT Impact, Adoption, and Best Practices
Medable, the leading provider of AI-powered clinical trial technology, today announced its Innovation Evidence Workshop series, developed in collaboration with and facilitated by the Tufts Center for the Study of Drug Development (Tufts CSDD). Leaders from 20 pharmaceutical, biotech, and contract research organizations (CROs) participated in the inaugural invitation-only workshop held on November 19 in Boston, MA. Programming featured representatives from the U.S. Food and Drug Administration, global pharmaceutical companies, leading contract research organizations (CROs), Harvard MRCT, Tufts CSDD, and Medable.
Medable Named a Leader Amid Growing eCOA Adoption
Everest Group’s 2025 Life Sciences eCOA PEAK Matrix® Assessment highlights Medable eCOA leadership in ease of use, AI innovation, and patient-centered design
.webp)
Medable Launches The Industry’s First Agentic AI Platform and CRA Agent; Removes Bottlenecks in Clinical Development
Agent Studio marks a turning point in clinical research, moving from human-heavy processes to scalable agents that streamline work and accelerate trials
Medable Launches Partner Program for Faster Clinical Trial Startup, Greater Control, and Transparent Pricing
Medable unveils its new Partner Program, designed to empower contract research organizations (CROs) and other partners with generative AI-driven, self-service eCOA build capabilities for digitally enabled clinical trials.
Medable Introduces Long-Term Follow-Up Model for Cell & Gene Therapy (CGT) Trials to Reduce Costs and Improve Patient Access
Medable unveils its digital-first, Long-Term Follow-Up (LTFU) model for cell and gene therapy (CGT) trials. Medable’s platform reduces the burden on patients and sites involved in complex CGT trials and enhances scientific integrity with sustainable data capture across the FDA-required 15-year follow-up period for certain CGTs, including those using genome-editing techniques.
Medable Releases New Digital Oncology Trial Offering to Reduce Complexity for Sites, Sponsors, Patients, and Caregivers
Integrated solution with self-service capabilities simplifies trial experience for all
Medable Achieves Landmark CNIL Approval, Expanding Access for Digital Clinical Trials Across the European Union
Medable announced that its eConsent and eCOA solutions have been approved for use in two clinical studies in eight countries outside of the European Union by France’s Commission Nationale de l’Informatique et des Libertés (CNIL).
New Data Reveals DCT Components Linked to Improvements in Clinical Trial Access Among Underrepresented Communities
Medable's groundbreaking study with the Tufts PACT Consortium highlights the transformative impact of decentralized clinical trials (DCTs) on diversity.
Medable Reports 80% Revenue Growth from Portfolio-Level eCOA Adoption, Sharp Increase Compared to Study-by-Study Adoption
Medable reports 80% revenue growth from portfolio-level eCOA adoption in 2024, reflecting growing confidence in scalable digital solutions for clinical trials.